Youssef-MY, Suduku-HA Eissa-MM, et al. Topical application o! ivermectin for human ectoparasites. Am J Trop, Med, Hyg. 1995; 53(6): 652-3.

https://doi.org/10.4269/ajtmh.1995.53.652

Currie BJ., M re-GP Wood-Yk. Ivernectin and crusted (Norwegian) scabies [letter]. Med J, Aust, 1995; 163(10): 5559-60.

https://doi.org/10.5694/j.1326-5377.1995.tb124745.x

JenickT, Nothdurft-HD, Rieder-N, LoscherT. Cutaneous myiasis reviewoIT3cases in travelers returning from tropical countries Int J Dermatol, 1995; 34(9); 624-6.

https://doi.org/10.1111/j.1365-4362.1995.tb01088.x

Okello-DO, Ovuga-EB, Ogwal-Okcng JW. Dennatological problems oí onchocerciasis in Nebbi District, Uganda. East Air Med J 1995; 72(5):295-8.

Baraka OZ, Mahmoud-BM, Ali-MM, Alí-MM, et al. Ivermectin trealment in severe asynumetric reactive onchodermatitis (sowda) in Sudan. Trans R Soc Trop Med Hyg. 1995; 89(3): 312-5.

https://doi.org/10.1016/0035-9203(95)90559-6

Meinking TL, Taplin D; Hermida JL, Pardo R, et al. The treatment of scabies with ivermectin, N Engl J Med. 1995; 333(1); 26-30.

https://doi.org/10.1056/NEJM199507063330105

Rodríguez Peréz MA, Rodíguez MH, Margeli Perez HM; et al. Effect of semiannual treatments of ivermectin on the prevalence and intensity of Onchocerca volvulus skin, ocular lesions, and infectivity of simulium ochraceum populations in southern Mexico, Am J Trop Med Hyg. 1995; 52(5):429-34

Burnham, G. Ivermectin treatment of onchocercal skin lesions: observation from a placebo controlled, double-blind trial in Malawi. Am J Trop Med Hyg. 1995; 52(3): 270-6.

https://doi.org/10.4269/ajtmh.52-270

Aubin , K, Humbert, R Ivermectin for crusted (Norwegian) scabies [letter] N Engl J Med. 1995; 332(9): 612.

https://doi.org/10.1056/NEJM199503023320917

Sieghart, W.: Structure and pharmacology of Gamma Aminobutyric Acid A Receptor subtypes. Pharmacogical Reviews. 1995; 47(2): 181-231.

Glazoiu P, Nyguyen,L.N., Moulia-Pelat, J. Petal.: Efficacy of ivermectin for the treatmen of head lice (Pediculosis capitis). Trop Med Parasitol. 1994; 45(3): 253-4.

Alley, E.S., Plaiser, A.R, Boatin , B.A., Dadzie K.Y., et al.: The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana. Trans R Soc Trop Med Hyg. 1994; 88 (5). 581-4.

https://doi.org/10.1016/0035-9203(94)90172-4

Marty-R Gari-Toussaint M, Le Eichoux Y, Gitxotte P, Efficacy of ivermectin in the treatment of an epidémica of sarcoptic seabies. Ann Trop Med-Parasitol. 1994; 88(4):453.

https://doi.org/10.1080/00034983.1994.11812890

Caumes E, Datry A, Mayorga R, et al. Efficacy of ivermectin in the therapy of larva currens [letter]. Arch Dermatol. 1994; 130(7); 932.

https://doi.org/10.1001/archderm.1994.01690070128022

Kar Sk ; Mania J; Patnaik S. The use of ivermectin for scabies. Natl Med J. India. (1994; 7(1); 15-6.

Macotela Ruiz E; Peña-González G. Tratamiento de la escabiasis con ivermectina por via oral, Gac Med. Mex. 1993; 129(3): 201-5.

Glazou P, Cartel. JL, Alzieu P, et al. Comparison of ivermectin and benzyl benzoate for tretament of scabies. Trop Med Parasitol. 1993: 120(S): 571-3.

Caumes E; Gentilini M Traitement de la larva migrans cutanee ankykistimienne. Ann Dermatol Venereol. 1993; 120(8) : 571-3.

Carriere-E, Carriere J, Datry A, et al. Arandomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop-Med-Hvg. 1993;49(5); 641-4.

https://doi.org/10.4269/ajtmh.1993.49.641

Wolf P, Ochsendorf FR, Milbradt R, Aktuelle Therapiemoglichkeiten bei larva migrans cutanea. Hautarzt, 1993; 44(7): 462-5.

Young PN, Traore S, Wanu S, et al. Ivermectin in human onchocerciasis: a clinical patologiad study of skin lesions before and three days after treatmen. Ann Parasitol Hum Comp. 1992; 67(6): 194-6.

https://doi.org/10.1051/parasite/1992676194

Louis FJ; de Quincenet G; Louis JP. Internet de l'ivermectine en prise unique dans le traitement du syndrome de larva migrans cutanee. Presse-Med. 1992; 21(31): 1483.

Chijioke CP, Okonkwo PO . Adverse events following mass ivemectin therapy for onehocerciasis. Trans R Soc Trop Med Hyg 1992; 86(3):284-6.

https://doi.org/10.1016/0035-9203(92)90310-9

Collins RC, Gonzalez Peralta C, Castro J, et al. Ivermectin: reduction in prevalence and infection intensity of Onchocerce volvulus following biannual treatments in five Guatemalan communictis. Am J Trop Med Hyg. 1992; 47(2)156-69.

https://doi.org/10.4269/ajtmh.1992.47.156

Caumes-E, Datry A, Paris L, et al. Efficacy of ivermectin in the therapy of cutaneous larva migrans [letter]. Arch Dermatol. 1992; 128(7): 994-5.

https://doi.org/10.1001/archderm.1992.01680170130027

Dunne CL, Malone CJ, Whitworth JA. A field study of the effects of ivermectin on ectoparasites of man Trans R Soc Trop Med Hyg. 1991, 35(4):550-1

https://doi.org/10.1016/0035-9203(91)90255-W

Pacque M, Greene BM, Muñoz B, Taylor HR, Ivermectin therapy: a 5 year follow up [letter]. J Infect Dis. 1991; 164(5); 1035-6.

https://doi.org/10.1093/infdis/164.5.1035

Pacque M, Elmets C, Dukuly-ZD, Muñoz B, et al. improvement in severe onchocercal skin disease after a single dose if ivermectin. Am J Med. 1991; 90(5): 590-4.

https://doi.org/10.1016/S0002-9343(05)80010-5

Mumcuogh KY, Miller J, Rosen LJ, Galun R. Systemic activity of ivermectin on the human body louse (Anoplura: Pediculidae). J Med-Entomol. 1990 Jan; 27(l):72-5.

https://doi.org/10.1093/jmedent/27.1.72

Maso MJ, Kapila R, Schwartz RA, et al, Cutaneous onchocerciasis. Int J Dermatol. 1987; 26(9):593-6.

https://doi.org/10.1111/j.1365-4362.1987.tb02313.x

Olsen, R.W., Snowman A.M.; Avermectin Bla modulation of gamma aminobutyric acid / benzodiazepine receptor binding in mammalian brain. J. Neuochem 1985; 44:1074-82.

https://doi.org/10.1111/j.1471-4159.1985.tb08727.x

Pong, S.S., Wang, C.C. The specificity of high affinity binding of avermectin Bla to mammalian brain. Neuropharmacology 1980; 19:311-17.

https://doi.org/10.1016/0028-3908(80)90155-0

Rennet, D.G. Clinical pharmacology of ivermectin. JAVMA., 1986; 189:100-3.